KN38-7271/BAY38-7271 – synthetic, CB1 & CB2 agonist

 

Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4- oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.        (full – 2002)  http://jpet.aspetjournals.org/content/302/1/359.long

 

BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.                                                     (abst – 2003)  http://www.ncbi.nlm.nih.gov/pubmed/14647528

 

Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271.                                                         (abst – 2003)

http://www.ncbi.nlm.nih.gov/pubmed/14519516

 

Breakthrough in treatment of Traumatic Brain Injury: KeyNeurotek’s clinical study reaches primary endpoint and shows significant increase in survival                                                                       (news – 2009)

 

 

 

 

 

 

 

 

http://www.drugs.com/clinical_trials/breakthrough-traumatic-brain-injury-keyneurotek-s-clinical-study-  reaches-primary-endpoint-shows-8667.html

 

Early Survival of Comatose Patients after Severe Traumatic Brain Injury with the Dual Cannabinoid CB1/CB2 Receptor Agonist KN38-7271: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.           (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22696266

 

Cannabinoid Receptor Subtypes 1 and 2 Mediate Long-Lasting Neuroprotection and Improve Motor Behaviour Deficits After Transient Focal Cerebral Ischemia.

(abst – 2012)                      http://www.ncbi.nlm.nih.gov/pubmed/23069763

Share a link for